PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417

por Montesinos, Pau, Al-Ali, Haifa Kathrin, Dominguez, Juan Manuel Alonso, Jentzsch, Madlen, Lavrencic, Mojca, Martelli, Maria Paola, Röllig, Christoph, Sica, Simona, Riham, Iadevaia, Yablonski, Kaitlin, Wang, Tianli, Mahmood, Zafar, Koenen, Giedre, Schmidt, Hank, Yang, Jingsing, Yee, Karen
Publicado 2023

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

por Postel-Vinay, Sophie, Lam, Vincent K, Ros, Willeke, Bauer, Todd M, Hansen, Aaron R, Cho, Daniel C, Stephen Hodi, F, Schellens, Jan H M, Litton, Jennifer K, Aspeslagh, Sandrine, Autio, Karen A, Opdam, Frans L, McKean, Meredith, Somaiah, Neeta, Champiat, Stephane, Altan, Mehmet, Spreafico, Anna, Rahma, Osama, Paul, Elaine M, Ahlers, Christoph M, Zhou, Helen, Struemper, Herbert, Gorman, Shelby A, Watmuff, Maura, Yablonski, Kaitlin M, Yanamandra, Niranjan, Chisamore, Michael J, Schmidt, Emmett V, Hoos, Axel, Marabelle, Aurelien, Weber, Jeffrey S, Heymach, John V
Publicado 2023